Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital
Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, today announced the closing of a $40M Series A financing round. The round was led by Khosla Ventures and Ahren Innovation Capital, with participation from Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital, LongeVC, Italian Angels for Growth (IAG), and other investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240422384739/en/
Rubedo Life Sciences scientists. Photo credit: ALESSANDRO GANDOLFI
The funding will be used to advance the company’s lead candidate RLS-1496 in chronic atopic dermatitis and chronic psoriasis, which will be entering Phase 1 studies. Rubedo is also developing additional therapies that selectively target senescent cells in pulmonary diseases with significant unmet medical need, such as idiopathic pulmonary fibrosis (IPF), with a program recipient of a substantial CIRM grant last year.
“We’re delighted to attract this top-tier syndicate co-led by Khosla Ventures and Ahren Innovation Capital. This significant influx of financing will allow us to advance our first clinical candidate into human studies,” said Marco Quarta, CEO & Co-Founder of Rubedo Life Sciences.
“As people live longer, improving quality of life is paramount,” said Alex Morgan, Partner, Khosla Ventures. “Rubedo is targeting senescent, or aging, cells that drive age-related diseases. This first trial can bring us another step closer to achieving better healthspan.”
“Our mission is to invest in transformational companies that will change the world for the better, serving vast markets,” said Alice Newcombe Ellis, Founding & General Partner, Ahren Innovation Capital. “We believe that Rubedo’s transformative approach to targeting senescent cells is an impressive step towards the development of chronic age-related therapies, which will advance biotech from treatment to prevention or disease reversal.”
“The significant experience and capital that our investors bring to Rubedo will help the company rapidly advance our programs,” said Ali Siam, Chief Business Officer, Rubedo Life Sciences. “We look forward to working with these leaders, whose vast experience in clinical development will be invaluable as we enter the next phase of growth at Rubedo.”
Rubedo’s Alembic™ drug discovery platform enables the identification of specific druggable targets for development into therapeutics that selectively target pathologic cells, such as various types of senescent cells, that drive the process of biological aging. Senescence is the process by which a cell ages and permanently stops dividing but does not die. Any cell can potentially become senescent. Over time, large numbers of senescent cells can build up in tissues throughout the body and release pathologic factors. When they reach a critical mass, they cause chronic inflammation and damage leading to fibrosis and tissue degeneration which drive many age-related diseases.
About Rubedo Life Sciences
Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target various types of senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, technology, and life sciences, with expertise in drug development and commercialization from both large pharma and leading biotech companies. The company is based in Sunnyvale, CA. For additional information, visit www.rubedolife.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422384739/en/
Contact information
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lenovo Group: First Quarter Financial Results 2025/2614.8.2025 02:52:00 EEST | Press release
Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today announced strong first quarter results for the fiscal year 2025/26, reporting significant growth in overall group revenue and profit. Revenue grew 22% year-on-year to US$18.8 billion, with net income up 108% year-on-year to US$505 million. On a non-Hong Kong Financial Reporting Standards (non-HKFRS[1]) basis, net income grew by 22% year-on-year to US$389 million, adjusted for non-cash fair value gain on warrants[2]. All main business groups saw solid double-digit year-on-year revenue growth, with the PC business reporting particularly strong numbers following the highest year-on-year revenue growth rate in 15 consecutive quarters and an all-time high market share of 24.6%. The Group’s diversified growth engines continue to grow, with non-PC revenue mix up nearly half a point year-on-year to 47%. All sales geographies delivered high to relatively high year-on-year revenue growth. The strong
Mobile Developers Now Get Greater Control of Their Revenue, Ownership of Their Data, and Direct-to-Consumer Capabilities With New Features for Xsolla’s Leading Web Shop14.8.2025 00:53:00 EEST | Press release
Xsolla, a leading global video game commerce company, announces significant updates to its leading Web Shop solution for mobile games, a modular solution that enables mobile developers to quickly generate direct-to-consumer stores in minutes or build fully customized storefronts with advanced features. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250813375229/en/ (Graphic: Xsolla) As developers face rising user acquisition costs and development expenses, varying regulations across regions, and high in-app fees, Xsolla Web Shop offers a strategic edge: a frictionless way to convert players into paying customers, retain them longer, expand monetization beyond the platforms, and operate LiveOps with more automation and reduced overhead. Key benefits of the easy plug-in new features in Xsolla Web Shop include: Automated and simplified operations. Cut operational overhead by up to 50% using real-time catalog sync, dynamic bundl
IFF to Webcast Fireside Chat at Barclays Global Consumer Staples Conference on Sept. 413.8.2025 23:15:00 EEST | Press release
IFF (NYSE: IFF) today announced that Chief Financial Officer Michael DeVeau will participate in a fireside chat at the Barclays Global Consumer Staples Conference on Thursday, Sept. 4, 2025 at 9 a.m. ET. Investors may access the live webcast on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20250813839035/en/
Xsolla Elevates Game Monetization and Distribution With Unified Web Shop and Offerwall13.8.2025 22:00:00 EEST | Press release
Xsolla, a global commerce company helping developers launch, grow and monetize their games, announces today the expansion of its Offerwall solution with full integration into Xsolla Web Shop, providing game developers with a fully unified and robust monetization stack. This marks the next phase of the Xsolla Offerwall's evolution, which officially launched in March. Additionally, the company announced the launch of the Xsolla Incentive Program, providing game developers with free user acquisition credits to help accelerate game growth by leveraging Xsolla’s commerce infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250813734646/en/ (Graphic: Xsolla) As game developers continue to face challenges monetizing non-paying players, the Xsolla Offerwall offers a new way to unlock value from their entire user base, by allowing players to earn in-game rewards by completing quests, app trials, surveys, and more directly w
G42 Launches OpenAI GPT-OSS Globally on Core42's AI Cloud13.8.2025 19:26:00 EEST | Press release
Core42, a G42 company specializing in sovereign cloud and AI infrastructure, announced the availability of OpenAI’s latest open-weight AI models, including gpt-oss-20B and gpt-oss-120B, on the Core42 AI Cloud platform, instantly accessible through the Core42 Compass API. The deployment enables enterprises, researchers, and developers to run the models on a choice of leading silicon platforms with sovereign, scalable, and high-performance capabilities. Integrated into Compass API with the flexibility to access a wide spectrum of high-performance compute platforms, Core42 delivers industry-leading inference speeds of up to 3,000 tokens per second per user, enabling real-time AI at global scale while aligning workloads with the optimal infrastructure for price-performance and scalability. This deployment delivers tailored performance for low-latency inference workloads and applications, reinforcing Core42’s commitment to secure and optimized global sovereign-enabled AI infrastructure. “Co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom